These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36416229)

  • 1. Pharmacokinetics, the Immunological Impact, and the Effect on HIV
    Leal L; Guardo AC; Bedoya LM; Rodríguez de Miguel C; Climent N; Rovira C; Beltrán M; Llach J; Alcamí J; Kashuba ADM; Gatell JM; Plana M; García F
    AIDS Res Hum Retroviruses; 2023 May; 39(5):211-221. PubMed ID: 36416229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
    Ford N; Shubber Z; Calmy A; Irvine C; Rapparini C; Ajose O; Beanland RL; Vitoria M; Doherty M; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3():S170-6. PubMed ID: 25972499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.
    McGowan I; Wilkin T; Landovitz RJ; Wu C; Chen Y; Marzinke MA; Hendrix CW; Richardson P; Eshleman SH; Andrade A; Chege W; Anderson PL; McCauley M; Farley J; Mayer KH; Anton P; Brand RM; Cranston RD; Gulick R
    AIDS; 2019 Feb; 33(2):237-246. PubMed ID: 30557160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
    Milinkovic A; Benn P; Arenas-Pinto A; Brima N; Copas A; Clarke A; Fisher M; Schembri G; Hawkins D; Williams A; Gilson R;
    J Antimicrob Chemother; 2017 Jun; 72(6):1760-1768. PubMed ID: 28369381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
    Leal L; León A; Torres B; Inciarte A; Lucero C; Mallolas J; Laguno M; Martínez-Rebollar M; González-Cordón A; Manzardo C; Rojas J; Pich J; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2016 Jul; 71(7):1982-6. PubMed ID: 26994091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
    Nishijima T; Gatanaga H; Shimbo T; Komatsu H; Endo T; Horiba M; Koga M; Naito T; Itoda I; Tei M; Fujii T; Takada K; Yamamoto M; Miyakawa T; Tanabe Y; Mitsuya H; Oka S;
    PLoS One; 2013; 8(8):e73639. PubMed ID: 23951362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis of post-exposure prophylaxis randomized clinical trials.
    Fernández I; de Lazzari E; Inciarte A; Diaz-Brito V; Milinkovic A; Arenas-Pinto A; Etcheverrry F; García F; Leal L;
    HIV Med; 2021 Mar; 22(3):218-224. PubMed ID: 33108035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
    Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
    Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
    Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
    Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
    N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.
    Sekabira R; McGowan I; Yuhas K; Brand RM; Marzinke MA; Manabe YC; Frank I; Eron J; Landovitz RJ; Anton P; Cranston RD; Anderson P; Mayer KH; Amico KR; Wilkin TJ; Chege W; Kekitiinwa AR; McCauley M; Gulick RM; Hendrix CW
    AIDS; 2021 Aug; 35(10):1585-1595. PubMed ID: 33831911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
    Leal L; León A; Torres B; Inciarte A; Lucero C; Mallolas J; Laguno M; Martínez-Rebollar M; González-Cordón A; Manzardo C; Rojas J; Pich J; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2016 Jul; 71(7):1987-93. PubMed ID: 26994089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.
    Reynes J; Trinh R; Pulido F; Soto-Malave R; Gathe J; Qaqish R; Tian M; Fredrick L; Podsadecki T; Norton M; Nilius A
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):256-65. PubMed ID: 22730929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
    Thomas R; Galanakis C; Vézina S; Longpré D; Boissonnault M; Huchet E; Charest L; Murphy D; Trottier B; Machouf N
    PLoS One; 2015; 10(11):e0142534. PubMed ID: 26559816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
    Martin A; Moore CL; Mallon PW; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA;
    PLoS One; 2013; 8(10):e77138. PubMed ID: 24204757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
    Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.